JP2016520075A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520075A5
JP2016520075A5 JP2016513387A JP2016513387A JP2016520075A5 JP 2016520075 A5 JP2016520075 A5 JP 2016520075A5 JP 2016513387 A JP2016513387 A JP 2016513387A JP 2016513387 A JP2016513387 A JP 2016513387A JP 2016520075 A5 JP2016520075 A5 JP 2016520075A5
Authority
JP
Japan
Prior art keywords
concentration
formulation
vwf
binding agent
tween
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016513387A
Other languages
English (en)
Japanese (ja)
Other versions
JP6433986B2 (ja
JP2016520075A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/060107 external-priority patent/WO2014184352A1/en
Publication of JP2016520075A publication Critical patent/JP2016520075A/ja
Publication of JP2016520075A5 publication Critical patent/JP2016520075A5/ja
Priority to JP2018209611A priority Critical patent/JP6952019B2/ja
Application granted granted Critical
Publication of JP6433986B2 publication Critical patent/JP6433986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016513387A 2013-05-17 2014-05-16 免疫グロブリン単一可変ドメインの安定製剤及びその使用 Active JP6433986B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018209611A JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824523P 2013-05-17 2013-05-17
US61/824,523 2013-05-17
PCT/EP2014/060107 WO2014184352A1 (en) 2013-05-17 2014-05-16 Stable formulations of immunoglobulin single variable domains and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018209611A Division JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Publications (3)

Publication Number Publication Date
JP2016520075A JP2016520075A (ja) 2016-07-11
JP2016520075A5 true JP2016520075A5 (enExample) 2017-06-15
JP6433986B2 JP6433986B2 (ja) 2018-12-05

Family

ID=49304267

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016513387A Active JP6433986B2 (ja) 2013-05-17 2014-05-16 免疫グロブリン単一可変ドメインの安定製剤及びその使用
JP2018209611A Active JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018209611A Active JP6952019B2 (ja) 2013-05-17 2018-11-07 免疫グロブリン単一可変ドメインの安定製剤及びその使用

Country Status (25)

Country Link
US (2) US10035862B2 (enExample)
EP (2) EP3511018B1 (enExample)
JP (2) JP6433986B2 (enExample)
KR (1) KR102166399B1 (enExample)
CN (3) CN105339003B (enExample)
AU (3) AU2014267222B2 (enExample)
BR (1) BR112015028411B1 (enExample)
CA (1) CA2912670A1 (enExample)
CY (1) CY1122090T1 (enExample)
DK (1) DK2996720T3 (enExample)
ES (2) ES2895150T3 (enExample)
HR (1) HRP20190954T1 (enExample)
HU (1) HUE044392T2 (enExample)
LT (1) LT2996720T (enExample)
MX (2) MX387527B (enExample)
NL (1) NL1040254C2 (enExample)
PH (1) PH12015502591B1 (enExample)
PL (2) PL3511018T3 (enExample)
PT (2) PT2996720T (enExample)
RS (1) RS58857B1 (enExample)
RU (1) RU2671977C2 (enExample)
SI (1) SI2996720T1 (enExample)
SM (1) SMT201900359T1 (enExample)
TR (1) TR201908663T4 (enExample)
WO (1) WO2014184352A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
CA2971278C (en) 2014-12-19 2023-09-19 Ablynx N.V. Cysteine linked nanobody dimers
CN111035754A (zh) * 2016-03-23 2020-04-21 兆科药业（合肥）有限公司 抗血小板溶栓素在制备治疗血栓性血小板减少性紫癜的药物中的应用
GB201612043D0 (en) 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
EP3534963B1 (en) * 2016-11-02 2024-04-17 Polaris Group Formulations of pegylated arginine deiminase
MY204220A (en) 2018-02-06 2024-08-16 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
MY207630A (en) 2018-07-03 2025-03-06 Fennec Pharmaceuticals Inc Formulations of anhydrous sodium thiosulfate
WO2020051307A1 (en) * 2018-09-05 2020-03-12 Ventria Bioscience Inc. Formulations of immunoglobulin a
EP3865154A4 (en) * 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
CN110564841A (zh) * 2019-09-19 2019-12-13 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 脑缺血相关基因作为缺血性卒中行为学特征分析的生物标记的应用
CN110624105B (zh) * 2019-09-24 2021-06-11 苏州大学 血管性血友病因子的结构敏感多肽抗原的序列
JP7502861B2 (ja) * 2019-12-27 2024-06-19 旭化成株式会社 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法
CN113908254B (zh) * 2021-10-19 2024-05-28 山西锦波生物医药股份有限公司 一种干粉吸入剂及其制备方法和用途
CN115850493B (zh) * 2022-11-08 2024-03-12 江苏耀海生物制药有限公司 一种二价纳米抗体Cablivi的分离纯化方法
WO2025240928A1 (en) * 2024-05-16 2025-11-20 Vega Therapeutics, Inc. Treatment of von willebrand disease

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
WO1995031479A1 (en) 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU740043B2 (en) 1996-06-27 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
WO2000040968A1 (en) 1999-01-05 2000-07-13 Unilever Plc Binding of antibody fragments to solid supports
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
JP2002535993A (ja) 1999-02-05 2002-10-29 リイクスニフェルシタイト ライデン 組換え体細胞における代謝物の生合成を変調する方法
WO2000055318A2 (en) 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
ID30380A (id) 1999-04-22 2001-11-29 Unilever Nv Penghambatan infeksi virus menggunakan protein pengikat antigen bervalensi tunggal
ATE422545T1 (de) 1999-06-18 2009-02-15 Cv Therapeutics Inc Regulierung mittels atp binding cassette transporter proteins abc1
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
DK1233987T3 (da) 1999-11-29 2009-09-28 Bac Ip B V Immobiliserede enkelt-domæne antigenbindende molekyler
EP1242460B1 (en) 1999-11-29 2006-10-18 Unilever Plc Immobilisation of proteins using a polypeptide segment
EP1134231B1 (en) 2000-03-14 2009-04-15 Unilever N.V. Antibody heavy chain variable domains against human dietary lipases, and their uses
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
US20040053340A1 (en) 2000-12-13 2004-03-18 De Haard Johannes Joseph Protein arrays
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US6723359B2 (en) 2001-10-18 2004-04-20 Firmenich Sa Spray-dried compositions and method for their preparation
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
EP1565482B1 (en) 2002-10-23 2014-04-30 Ludwig Institute for Cancer Research Ltd. A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
PL1836500T3 (pl) 2005-01-14 2010-12-31 Ablynx Nv Sposoby i testy do rozróżniania między różnymi postaciami chorób i zaburzeń cechujących się małopłytkowością i/lub samoistną interakcją między czynnikiem von Willebranda (vWF) a płytkami krwi
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
DK2444424T3 (en) * 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
CN101262885B (zh) * 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
WO2007104529A2 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
WO2008116103A2 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
TW201731488A (zh) * 2007-12-28 2017-09-16 巴克斯歐塔公司 重組ｖｗｆ調配物
BRPI0907186A2 (pt) * 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
EP2252303A2 (en) * 2008-03-21 2010-11-24 Ablynx NV Von willebrand factor specific binders and methods of use therefor
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
HRP20130414T1 (en) * 2008-10-21 2013-06-30 Baxter International Inc. Lyophilized recombinant vwf formulations
EP2362767B1 (en) * 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
EP2506874A1 (en) 2009-12-01 2012-10-10 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
EP2533761B1 (en) * 2010-02-11 2019-03-27 Ablynx N.V. Methods and compositions for the preparation of aerosols
US20120225072A1 (en) * 2011-03-02 2012-09-06 Ablynx N.V. Stable formulations of immunoglobulin single variable domains and uses thereof
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.

Similar Documents

Publication Publication Date Title
JP2016520075A5 (enExample)
RU2015154214A (ru) Стабильные композиции иммуноглобулинового одиночного вариабельного домена и их применение
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
JP2015231997A5 (enExample)
JP2013079270A5 (enExample)
JP2015091902A5 (enExample)
EA201892446A1 (ru) Фармацевтическая композиция
CN102892424B (zh) 病毒颗粒的稳定
JP2013543505A5 (enExample)
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
JP2012136518A5 (enExample)
WO2013164789A3 (en) Lyophilised and aqueous anti-cd40 antibody formulations
AR082171A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ngf
TN2009000382A1 (en) Stable antibody formulations
RU2017101667A (ru) Фармацевтические композиции
RU2011127913A (ru) Составы, содержащие антитела
JP2009292810A5 (enExample)
JP2017514868A5 (enExample)
RU2014124143A (ru) Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
HRP20220011T1 (hr) Nova stabilna formulacija za fxia protutijela
HRP20211838T1 (hr) Krnji protein vp4 rotavirusa i njegova primjena
EA202092926A2 (ru) Лиофилизированные составы, содержащие фактор ix
HRP20181021T1 (hr) Formulacija za bispecifične aktivatore limfocita t (bites)
PH12021551307A1 (en) Protein solution formulation containing high concentration of an anti-vegf antibody
RU2019111152A (ru) Новый способ стабилизации биофармацевтического лекарственного продукта при производстве